ARCUTIS BIOTHERAPEUTICS, INC. Payments of Debt Issuance Costs
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Payments of Debt Issuance Costs of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2025-02-25
- ARCUTIS BIOTHERAPEUTICS, INC. payments of debt issuance costs for the quarter ending 2023-12-31 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. payments of debt issuance costs for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. payments of debt issuance costs for the quarter ending 2021-12-31 was $1.64M.
- ARCUTIS BIOTHERAPEUTICS, INC. payments of debt issuance costs for fiscal 2024 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. payments of debt issuance costs for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. payments of debt issuance costs for fiscal 2022 was $2.19M, a 33.60% increase from fiscal 2021.
- ARCUTIS BIOTHERAPEUTICS, INC. payments of debt issuance costs for fiscal 2021 was $1.64M.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-25 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 10-K · filed 2025-02-25 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-03 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $2.19M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $2.19M 10-Q · filed 2023-11-03 | ||
| 2021-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.64M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 | ||
| 2019-12-31 | $0.00 10-K · filed 2022-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |